Vertex Pharmaceuticals Incorporated


SKU: VRTX Category:


This is our first report on the global market leader in cystic fibrosis, Vertex Pharmaceuticals. The company is off to quite an excellent start in 2022 with swift advancement of the pipeline. The management saw a 22% growth in the CF product revenues in the most recent quarter. It has a phenomenal liquidity of $8.2 billion giving the management a lot of leeway to invest in R&D. Among recent updates, Vertex announced PRIME (Priority Medicine) designation by the EMA and VX-147 (Inaxaplin) granted breakthrough therapy designation through the U.S. FDA. The EMA has granted inaxaplin PRIME (Priority Medicines) designation for AMKD (APOL1-mediated chronic kidney disease. Also, the company announced an expansion further in the Boston Seaport for Genetic and Cell Therapies of the Jeffrey Leiden Centre. The R&D strategy of the company, along with its business model, has positioned it quite well for sustained growth and continued innovation. We initiate coverage on the stock of Vertex Pharmaceuticals with a ‘Hold’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!